Posted by Michael Wonder on 25 Aug 2025
Health Canada approves Roche’s Columvi (glofitamab) as the first bi-specific antibody in Canada for relapsed or refractory diffuse large B-cell lymphoma after initial therapy
21 August 2025 - Approval is based on Phase 3 STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to Rituxan plus chemotherapy.
Roche Canada is pleased to announce that Health Canada has granted market authorisation for Columvi (glofitamab for injection) in combination with gemcitabine and oxaliplatin indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified who are not candidates for autologous stem cell transplant.
